Ozempic Shortage UK 2026: Alternatives & What to Do

Ozempic (semaglutide 0.25 mg, 0.5 mg, and 1 mg injection pens) has experienced intermittent supply disruptions across the UK since late 2022. As of early 2026, shortages persist — though the situation has improved compared to 2023–2024.

The Medicines and Healthcare products Regulatory Agency (MHRA) and the Department of Health and Social Care (DHSC) have issued multiple Serious Shortage Protocols (SSPs) allowing pharmacists to substitute alternative semaglutide products or adjust dispensing quantities without a new prescription.

If you rely on Ozempic for type 2 diabetes management or weight loss, understanding the supply picture and your options is essential.

Several factors have converged to create sustained supply pressure:

Unprecedented demand: The global popularity of GLP-1 agonists for weight management has dramatically outstripped Novo Nordisk's manufacturing capacity. Ozempic was originally developed for type 2 diabetes, but off-label and on-label weight-loss prescribing has surged.

Manufacturing complexity: Semaglutide is a modified peptide produced through complex biotechnological processes. Scaling production requires new manufacturing facilities that take years to build and validate.

Global competition for supply: The UK competes with every other market for the same production output. Countries with higher reimbursement prices or larger contracts may receive preferential allocation.

Parallel exports: Some UK-allocated stock has been exported to higher-price markets, further reducing domestic availability. The DHSC has taken steps to limit this, but enforcement remains imperfect.

Wegovy launch effects: The UK launch of Wegovy (higher-dose semaglutide for weight management) has placed additional strain on Novo Nordisk's semaglutide supply chain.

If your pharmacy cannot fulfil your Ozempic prescription, take these practical steps:

1. Contact your prescriber promptly — do not simply skip doses. Your GP or specialist can assess whether a dose adjustment, temporary switch, or alternative medication is appropriate.

2. Check multiple pharmacies — supply can vary between branches and wholesalers. Your prescriber's practice may know which local pharmacies currently have stock.

3. Ask about the Serious Shortage Protocol — pharmacists can dispense an alternative semaglutide product (such as a different pen strength) under SSP provisions without requiring a new prescription.

4. Do not buy from unregulated online sources — counterfeit semaglutide products have been seized in the UK. Only obtain medications through legitimate pharmacies and prescribers.

5. Do not share pens or adjust doses independently — multi-dose pens are for single-patient use only. Dose changes should always be supervised by your prescriber.

6. Request a bridging prescription — if switching to an alternative, your GP can provide a short bridging prescription to avoid gaps in treatment.

Several alternatives to Ozempic may be available depending on your indication and eligibility:

Wegovy (semaglutide 2.4 mg) — the same active ingredient at a higher dose, licensed specifically for weight management. Availability has also been constrained but is improving as Novo Nordisk expands production.

Mounjaro (tirzepatide) — a dual GIP/GLP-1 receptor agonist from Eli Lilly. Clinical trials suggest comparable or superior weight loss to semaglutide. NICE has approved tirzepatide for type 2 diabetes, and it received a positive NICE recommendation (TA924) for weight management in November 2024.

Saxenda (liraglutide 3 mg) — an older GLP-1 agonist requiring daily injection (vs. weekly for semaglutide). Less potent for weight loss than semaglutide or tirzepatide, but more widely available.

Trulicity (dulaglutide) — a weekly GLP-1 agonist approved for type 2 diabetes. Not licensed for weight management in the UK but may be an option for diabetes patients affected by the Ozempic shortage.

Rybelsus (oral semaglutide) — tablet form of semaglutide for type 2 diabetes. Lower bioavailability than injectable semaglutide, but an option if injection supply is limited.

Your prescriber will consider your specific clinical situation, NICE guidance, and local formulary availability when recommending an alternative.

Novo Nordisk has invested heavily in expanding manufacturing capacity. The company has committed over $10 billion to new production facilities, with several expected to come online between 2026 and 2028.

Industry analysts anticipate that:

• •Late 2026: Supply should improve significantly as new capacity starts contributing to global output
• •2027: Near-normal supply is expected for most markets, including the UK
• •Long term: Additional GLP-1 agonist competition (from Eli Lilly, Amgen, Pfizer, and others) should ease overall supply pressure across the class

However, demand continues to grow as eligibility criteria expand and public awareness increases. Supply normalisation depends on manufacturing expansion outpacing demand growth.

The MHRA publishes supply updates and Serious Shortage Protocols on its website. Your pharmacist and prescriber are the best sources of real-time local availability information.

The Ozempic shortage is a global manufacturing challenge, not a UK-specific issue. While supply is improving, disruptions may continue through 2026.

What to remember:

• •Never stop or adjust your medication without consulting your prescriber
• •Legitimate alternatives exist — your GP can help you switch safely
• •Avoid unregulated online sellers; counterfeit GLP-1 products are a real and growing risk
• •Supply is expected to improve significantly by late 2026 as manufacturing capacity expands
• •If you are using Ozempic for type 2 diabetes, you may be prioritised for supply over weight-management patients

*This article is for informational purposes only and does not constitute medical advice. Always consult your GP or prescribing clinician for personalised guidance.*